132 related articles for article (PubMed ID: 38564927)
21. A Suggested Prognostic Reclassification of Intermediate and Poor-Risk Nonseminomatous Germ Cell Tumors.
Necchi A; Pond GR; Nicolai N; Giannatempo P; Raggi D; Adra N; Hanna NH; Salvioni R; Einhorn LH; Albany C
Clin Genitourin Cancer; 2017 Apr; 15(2):306-312.e3. PubMed ID: 27594554
[TBL] [Abstract][Full Text] [Related]
22. [Treatment of testicular germ cell tumors relapse].
Carbonnaux M; Vinceneux A; Peyrat P; Fléchon A
Bull Cancer; 2020 Sep; 107(9):912-924. PubMed ID: 32653158
[TBL] [Abstract][Full Text] [Related]
23. Maintenance Oral Etoposide After High-Dose Chemotherapy (HDCT) for Patients With Relapsed Metastatic Germ-Cell Tumors (mGCT).
Taza F; Abonour R; Zaid MA; Althouse SK; Anouti B; Akel R; Hanna NH; Adra N; Einhorn LH
Clin Genitourin Cancer; 2023 Apr; 21(2):213-220. PubMed ID: 36737276
[TBL] [Abstract][Full Text] [Related]
24. Excellent survival in relapsed stage I testicular cancer.
Speicher P; Fankhauser CD; Lorch A; Ardizzone D; Helnwein S; Hoch D; Hermanns T; Beyer J; Akhoundova D
BMC Cancer; 2023 Sep; 23(1):870. PubMed ID: 37715132
[TBL] [Abstract][Full Text] [Related]
25. Multicenter Database of Patients with Germ-Cell Tumors: A Latin American Cooperative Oncology Group Registry (LACOG 0515).
Bastos DA; Gongora ABL; Dzik C; Jardim DL; Piva M; Carcano FM; Bertollo G; Trindade K; Fontes MS; Soares A; Reinert T; De Cassia Costamilan R; Villarroel RU; Watarai G; Gazola AA; Preto DDA; Mutti H; Bonalumi Dos Santos M; Mariano RC; Binotto M; Carvalho MM; Oliveira VPDC; Gomes R; Rebelatto TF; Schutz FA; Smaletz O; Fay AP
Clin Genitourin Cancer; 2023 Jun; 21(3):e104-e113. PubMed ID: 36509612
[TBL] [Abstract][Full Text] [Related]
26. The management and survival of patients with advanced germ-cell tumours: improving outcome in intermediate and poor prognosis patients.
Bhala N; Coleman JM; Radstone CR; Horsman JM; George J; Hancock BW; Hatton MQ; Coleman RE
Clin Oncol (R Coll Radiol); 2004 Feb; 16(1):40-7. PubMed ID: 14768754
[TBL] [Abstract][Full Text] [Related]
27. Pre-orchiectomy tumor marker levels should not be used for International Germ Cell Consensus Classification (IGCCCG) risk group assignment.
Fankhauser CD; Gerke TA; Roth L; Sander S; Grossmann NC; Kranzbühler B; Eberli D; Sulser T; Beyer J; Hermanns T
J Cancer Res Clin Oncol; 2019 Mar; 145(3):781-785. PubMed ID: 30637464
[TBL] [Abstract][Full Text] [Related]
28. Surgical Management of Cervical Non-seminomatous Germ Cell Tumor Metastases.
Nwosu OI; Jones AJ; Alwani M; Einhorn LH; Moore MG; Mantravadi AV
Laryngoscope; 2021 Jul; 131(7):1528-1534. PubMed ID: 33421136
[TBL] [Abstract][Full Text] [Related]
29. Prognostic Value of Teratoma in Primary Tumor and Postchemotherapy Retroperitoneal Lymph Node Dissection Specimens in Patients With Metastatic Germ Cell Tumor.
Taza F; Chovanec M; Snavely A; Hanna NH; Cary C; Masterson TA; Foster RS; Einhorn LH; Albany C; Adra N
J Clin Oncol; 2020 Apr; 38(12):1338-1345. PubMed ID: 32134699
[TBL] [Abstract][Full Text] [Related]
30. Multimodality treatment outcome in patients with primary malignant mediastinal germ cell tumor in adults.
Biswas B; Dabkara D; Sengupta M; Ganguly S; Ghosh J; Arunsingh S M; Sen S
Cancer Rep (Hoboken); 2021 Feb; 4(1):e1306. PubMed ID: 33029924
[TBL] [Abstract][Full Text] [Related]
31. Improved survival in metastatic germ-cell cancer.
Fankhauser CD; Sander S; Roth L; Beyer J; Hermanns T
Ann Oncol; 2018 Feb; 29(2):347-351. PubMed ID: 29161363
[TBL] [Abstract][Full Text] [Related]
32. Clinical impact of residual extraretroperitoneal masses in patients with advanced nonseminomatous germ cell testicular cancer.
Masterson TA; Shayegan B; Carver BS; Bajorin DF; Feldman DR; Motzer RJ; Bosl GJ; Sheinfeld J
Urology; 2012 Jan; 79(1):156-9. PubMed ID: 22202548
[TBL] [Abstract][Full Text] [Related]
33. A risk-adapted study of cisplatin and etoposide, with or without ifosfamide, in patients with metastatic seminoma: results of the GETUG S99 multicenter prospective study.
Fizazi K; Delva R; Caty A; Chevreau C; Kerbrat P; Rolland F; Priou F; Geoffrois L; Rixe O; Beuzeboc P; Malhaire JP; Culine S; Aubelle MS; Laplanche A
Eur Urol; 2014 Feb; 65(2):381-6. PubMed ID: 24094847
[TBL] [Abstract][Full Text] [Related]
34. Relationship between primary and metastatic testicular germ cell tumors: a clinicopathologic analysis of 100 cases.
Tarrant WP; Czerniak BA; Guo CC
Hum Pathol; 2013 Oct; 44(10):2220-6. PubMed ID: 23856516
[TBL] [Abstract][Full Text] [Related]
35. Contemporary North-American population-based validation of the International Germ Cell Consensus Classification for metastatic germ cell tumors of the testis.
Mazzone E; Knipper S; Mistretta FA; Tian Z; Palumbo C; Soulieres D; De Cobelli O; Montorsi F; Shariat SF; Saad F; Briganti A; Karakiewicz PI
World J Urol; 2020 Jun; 38(6):1535-1544. PubMed ID: 31463562
[TBL] [Abstract][Full Text] [Related]
36. Surveillance for stage I testicular germ cell tumours: results and cost benefit analysis of management options.
Francis R; Bower M; Brunström G; Holden L; Newlands ES; Rustin GJ; Seckl MJ
Eur J Cancer; 2000 Oct; 36(15):1925-32. PubMed ID: 11000572
[TBL] [Abstract][Full Text] [Related]
37. Clinical Characteristics and Treatment Outcomes of Patients With Advanced Germ Cell Tumor Treated at a Tertiary Cancer Center in Brazil.
Vasconcellos VF; Bastos DA; Pereira AAL; Watarai GY; Pereira BR; de Godoy A; Almeida-Silva J; Muniz DQB; Guglielmetti GB; Nahas WC; Dzik C
J Glob Oncol; 2019 Feb; 5():1-8. PubMed ID: 30779600
[TBL] [Abstract][Full Text] [Related]
38. Residual tumor size and IGCCCG risk classification predict additional vascular procedures in patients with germ cell tumors and residual tumor resection: a multicenter analysis of the German Testicular Cancer Study Group.
Winter C; Pfister D; Busch J; Bingöl C; Ranft U; Schrader M; Dieckmann KP; Heidenreich A; Albers P
Eur Urol; 2012 Feb; 61(2):403-9. PubMed ID: 22078334
[TBL] [Abstract][Full Text] [Related]
39. An analysis of surveillance for stage I combined teratoma--seminoma of the testis.
Thomas R; Dearnaley D; Nicholls J; Norman A; Sampson S; Horwich A
Br J Cancer; 1996 Jul; 74(1):59-62. PubMed ID: 8679458
[TBL] [Abstract][Full Text] [Related]
40. Systemic inflammatory markers have independent prognostic value in patients with metastatic testicular germ cell tumours undergoing first-line chemotherapy.
Fankhauser CD; Sander S; Roth L; Gross O; Eberli D; Sulser T; Seifert B; Beyer J; Hermanns T
Br J Cancer; 2018 Mar; 118(6):825-830. PubMed ID: 29485982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
